Humanized Mouse and Rat Model Market by Type (Genetic Models, Cell-based Models (CD34, BLT, PMC), Rat Models), Application (Oncology, Immunology, Neuroscience, Toxicology, Infectious Diseases), End User (Pharma, Biotech) & Region - Global Forecast to 2028
The global humanized mouse and rat model market is projected to reach USD 349 million by 2028 from USD 259 million in 2023, at a CAGR of 6.2% during the forecast period of 2023 to 2028. CRISPR is set to gain significant demand to develop genetically modified mouse strains, attributive to affordability and faster outcomes associated with CRISPR. CRISPR has emerged as a potent gene editing technology for market players for genetic modification, developing a efficient genetic humanized mouse models.
Humanized mouse models segment accounted for the highest revenue share in the market in 2022.
Based on type, the humanized mouse and rat model market has been segmented into humanized mouse models and humanized rat models. In 2022, humanized mouse models have garnered the highest share in terms of revenue in the market. This segment is also expected to grow with a fastest CAGR through the forecast period. Increase in demand for cell-based humanized mouse models has contributed to the segment’s growth. These models are used for a wide range of applications, such as analyzing the safety and effectiveness of potential new drugs and in long-term studies in the fields of immuno-oncology, infectious diseases, and graft-versus-host disease.
The immunology & infectious diseases segment accounted for the second largest share of the market in 2022
Based on application, the humanized mouse and rat model market is segmented into oncology, immunology & infectious diseases, neuroscience, hematopoiesis, toxicology, and other applications. The immunology & infectious diseases segment is the second largest segment in the market in terms of revenue. Mouse models are used in immunology and inflammation studies as they help assess the physiological relevance of an experimental finding. Mouse models allow suitable alterations in the mouse genome at random or in specific regions, enabling a detailed study of immunological processes.
Europe is the second largest region in the humanized mouse and rat model market
The humanized mouse and rat model market is segmented into North America, Europe, Asia Pacific, Latin America (LATAM) and Middle East and Africa (MEA). A growing focus on combating cancer is a key factor driving market growth. This is evident with the formation of two prominent organizations in Europe—Cancer Core Europe and the EurOPDX Consortium (comprising 18 not-for-profit cancer centers and universities).
The primary interviews conducted for this report can be categorized as follows:
This report provides a detailed picture of the humanized mouse and rat model market. It aims at estimating the size and future growth potential of the market across different segments such as the type, application, end user, and region. The report also includes an in-depth competitive analysis of the key market players along with their company profiles recent developments and key market strategies.
Key Benefits of Buying the Report:
The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall humanized mouse and rat model market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, restraints, challenges, trends, and opportunities.
The report provides insights on the following pointers:
Humanized mouse models segment accounted for the highest revenue share in the market in 2022.
Based on type, the humanized mouse and rat model market has been segmented into humanized mouse models and humanized rat models. In 2022, humanized mouse models have garnered the highest share in terms of revenue in the market. This segment is also expected to grow with a fastest CAGR through the forecast period. Increase in demand for cell-based humanized mouse models has contributed to the segment’s growth. These models are used for a wide range of applications, such as analyzing the safety and effectiveness of potential new drugs and in long-term studies in the fields of immuno-oncology, infectious diseases, and graft-versus-host disease.
The immunology & infectious diseases segment accounted for the second largest share of the market in 2022
Based on application, the humanized mouse and rat model market is segmented into oncology, immunology & infectious diseases, neuroscience, hematopoiesis, toxicology, and other applications. The immunology & infectious diseases segment is the second largest segment in the market in terms of revenue. Mouse models are used in immunology and inflammation studies as they help assess the physiological relevance of an experimental finding. Mouse models allow suitable alterations in the mouse genome at random or in specific regions, enabling a detailed study of immunological processes.
Europe is the second largest region in the humanized mouse and rat model market
The humanized mouse and rat model market is segmented into North America, Europe, Asia Pacific, Latin America (LATAM) and Middle East and Africa (MEA). A growing focus on combating cancer is a key factor driving market growth. This is evident with the formation of two prominent organizations in Europe—Cancer Core Europe and the EurOPDX Consortium (comprising 18 not-for-profit cancer centers and universities).
The primary interviews conducted for this report can be categorized as follows:
- By Company- Tire 1-37%. Tire 2-23%, Tire 3-40%
- By Designation: C Level Executives – 32%, Director level - 26%, and others-42%
- By Region: North America -35%, Europe -25%, Asia-Pacific -20%, Latin America -12%, and Middle East and Africa – 8%
- Charles River Laboratories (US)
- THE JACKSON LABORATORY (JAX) (US)
- Taconic Biosciences, Inc. (US)
- Crown Biosciences (US)
- Champions Oncology, Inc. (US)
- Hera BioLabs (US)
- genOway (France)
- Inotiv (US)
- Vitalstar Biotechnology (China)
- Ingenious Targeting Laboratory (US)
- TRANS GENIC (Japan)
- Harbour Antibodies BV (Netherlands)
- Oncodesign (France)
- Pharmatest Services (Finland)
- Ozgene Pty Ltd. (Australia)
- TransCure bioServices (France)
- Cyagen Biosciences (US)
- Aragen Life Sciences Ltd. (India)
- GemPharmatech (China)
- Biocytogen (US)
This report provides a detailed picture of the humanized mouse and rat model market. It aims at estimating the size and future growth potential of the market across different segments such as the type, application, end user, and region. The report also includes an in-depth competitive analysis of the key market players along with their company profiles recent developments and key market strategies.
Key Benefits of Buying the Report:
The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall humanized mouse and rat model market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, restraints, challenges, trends, and opportunities.
The report provides insights on the following pointers:
- Analysis of key drivers (Growth in the humanized mouse and rat model market is majorly driven by the rising use of humanized models in drug discovery research, rising demand for personalized medicine, government-funded initiatives for cancer research, increasing R&D activities in pharmaceutical & biotechnology industry), restraints (High cost of custom humanized models, and regulatory compliance for ethical use of animal mode are expected to restrain the growth of this market during the forecast period), opportunities (Growing demand for humanized mouse models, preference for humanized PDX models, and emergence of CRISPR in biomedical research), challenges (Limitations of humanized mouse models and alternative methods for animal testing) are influencing the growth of humanized mouse and rat model market.
- Product Development/Innovation: Detailed insights on newly launched product, and technological assessment of the humanized mouse and rat model market.
- Market Development: Comprehensive information about lucrative markets – the report analyses the humanized mouse and rat model market across varied regions.
- Market Diversification: Exhaustive information about new product, untapped geographies, recent developments, and investments in the humanized mouse and rat model market.
- Competitive Assessment: In-depth assessment of market shares, growth strategies product offerings of leading players like Charles River Laboratories (US), THE JACKSON LABORATORY (JAX) (US), Taconic Biosciences, Inc. (US), Inotiv (US), among others in the humanized mouse and rat model market. The report also helps stakeholders understand the pulse of humanized mouse and rat model market and provides them information on key market drivers, restraints, challenges, and opportunities.
1 INTRODUCTION
1.1 STUDY OBJECTIVES
1.2 MARKET DEFINITION
1.2.1 INCLUSIONS AND EXCLUSIONS
1.3 MARKET SCOPE
1.3.1 MARKETS COVERED
1.3.2 YEARS CONSIDERED
1.4 CURRENCY CONSIDERED
1.5 LIMITATIONS
1.6 STAKEHOLDERS
1.7 SUMMARY OF CHANGES
2 RESEARCH METHODOLOGY
2.1 RESEARCH APPROACH
FIGURE 1 RESEARCH DESIGN
2.1.1 SECONDARY DATA
2.1.2 PRIMARY DATA
2.1.2.1 Breakdown of primary sources
FIGURE 2 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
2.2 PRIMARY INSIGHTS
2.3 MARKET SIZE ESTIMATION
FIGURE 3 HUMANIZED MOUSE AND RAT MODEL MARKET: MARKET SIZE ESTIMATION (SUPPLY-SIDE ANALYSIS)
FIGURE 4 MARKET SIZE ESTIMATION: APPROACH 1 (COMPANY REVENUE ANALYSIS-BASED ESTIMATION)
2.4 MARKET GROWTH RATE PROJECTIONS
FIGURE 5 HUMANIZED MOUSE AND RAT MODEL MARKET: CAGR PROJECTIONS
FIGURE 6 HUMANIZED MOUSE AND RAT MODEL MARKET: CAGR PROJECTIONS FROM ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
2.4.1 DATA TRIANGULATION AND MARKET BREAKDOWN
FIGURE 7 DATA TRIANGULATION METHODOLOGY
2.5 RESEARCH ASSUMPTIONS
2.6 RISK IMPACT ANALYSIS
2.7 RECESSION IMPACT ANALYSIS
TABLE 1 GLOBAL INFLATION RATE PROJECTIONS, 2024–2028 (% GROWTH)
TABLE 2 US HEALTH EXPENDITURE, 2019–2022 (USD MILLION)
TABLE 3 US HEALTH EXPENDITURE, 2023–2027 (USD MILLION)
3 EXECUTIVE SUMMARY
FIGURE 8 HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2023 VS. 2028 (USD MILLION)
FIGURE 9 HUMANIZED MOUSE AND RAT MODEL MARKET, BY APPLICATION, 2023 VS. 2028 (USD MILLION)
FIGURE 10 HUMANIZED MOUSE AND RAT MODEL MARKET, BY END USER, 2023 VS. 2028 (USD MILLION)
FIGURE 11 GEOGRAPHICAL SNAPSHOT OF HUMANIZED MOUSE AND RAT MODEL MARKET
4 PREMIUM INSIGHTS
4.1 HUMANIZED MOUSE AND RAT MODEL MARKET OVERVIEW
FIGURE 12 RISING USE OF HUMANIZED MODELS IN DRUG DISCOVERY RESEARCH TO DRIVE MARKET
4.2 ASIA PACIFIC: HUMANIZED MOUSE AND RAT MODEL MARKET, BY END USER AND COUNTRY
FIGURE 13 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES SEGMENT ACCOUNTED FOR LARGEST MARKET SHARE IN CHINA FOR 2022
4.3 NORTH AMERICA: CELL-BASED HUMANIZED MOUSE MODELS MARKET, BY TYPE (USD MILLION)
FIGURE 14 PBMC HUMANIZED MOUSE MODELS SEGMENT TO REGISTER HIGHER GROWTH RATE DURING FORECAST PERIOD
5 MARKET OVERVIEW
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
FIGURE 15 HUMANIZED MOUSE AND RAT MODEL MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
5.2.1 DRIVERS
5.2.1.1 Rising use of humanized models in drug discovery research
5.2.1.2 Growing preference for personalized medicine
5.2.1.3 Government-funded initiatives for cancer research
5.2.1.4 Increasing R&D activities in pharmaceutical & biotechnology industries
TABLE 4 NUMBER OF R&D PRODUCTS, BY INDICATION (2022)
5.2.2 RESTRAINTS
5.2.2.1 High cost of custom humanized models
5.2.2.2 Stringent regulatory compliance for ethical use of animal models
5.2.3 OPPORTUNITIES
5.2.3.1 Growing preference for humanized PDX models
5.2.3.2 Emergence of CRISPR in biomedical research
5.2.3.3 Rising demand for humanized rat models
5.2.4 CHALLENGES
5.2.4.1 Alternative methods for animal testing
5.2.4.2 Limitations of humanized mouse models
5.3 REGULATORY ANALYSIS
5.3.1 NORTH AMERICA
5.3.2 EUROPE
5.3.3 ASIA PACIFIC
5.3.3.1 China
5.3.3.2 Japan
5.3.3.3 India
5.3.3.4 Australia
5.3.4 LATIN AMERICA
5.3.5 MIDDLE EAST & AFRICA
5.4 PRICING ANALYSIS
TABLE 5 PRICE OF HUMANIZED MOUSE MODELS (2022)
5.5 TECHNOLOGY ANALYSIS
5.6 VALUE CHAIN ANALYSIS
FIGURE 16 CREATION OF HUMANIZED MODELS—MAXIMUM VALUE IS ADDED DURING IMPLANTATION OF GRAFT/TUMOR CELLS IN IMMUNODEFICIENT MICE OR RATS
5.7 ECOSYSTEM ANALYSIS
FIGURE 17 HUMANIZED MOUSE AND RAT MODEL MARKET: ECOSYSTEM MAP
TABLE 6 SUPPLY CHAIN ECOSYSTEM
5.8 PORTER’S FIVE FORCES ANALYSIS
TABLE 7 HUMANIZED MOUSE AND RAT MODEL MARKET: PORTER’S FIVE FORCES ANALYSIS
5.8.1 THREAT OF NEW ENTRANTS
5.8.2 THREAT OF SUBSTITUTES
5.8.3 BARGAINING POWER OF BUYERS
5.8.4 BARGAINING POWER OF SUPPLIERS
5.8.5 INTENSITY OF COMPETITIVE RIVALRY
5.9 PATENT ANALYSIS
5.10 KEY CONFERENCES AND EVENTS
5.10.1 HUMANIZED MOUSE AND RAT MODEL MARKET: KEY CONFERENCES AND EVENTS IN 2023
TABLE 8 HUMANIZED MOUSE AND RAT MODEL MARKET: KEY CONFERENCES AND EVENTS IN 2023
5.11 KEY STAKEHOLDERS AND BUYING CRITERIA
5.11.1 KEY STAKEHOLDERS IN BUYING PROCESS
FIGURE 18 HUMANIZED MOUSE AND RAT MODEL MARKET: INFLUENCE OF KEY STAKEHOLDERS ON BUYING PROCESS
5.11.2 HUMANIZED MOUSE AND RAT MODEL MARKET: KEY BUYING CRITERIA
FIGURE 19 KEY BUYING CRITERIA FOR END USERS
6 HUMANIZED MOUSE AND RAT MODEL MARKET, BY TYPE
6.1 INTRODUCTION
TABLE 9 HUMANIZED MOUSE AND RAT MODEL MARKET, BY TYPE, 2021–2028 (USD MILLION)
6.2 HUMANIZED MOUSE MODELS
TABLE 10 HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 11 HUMANIZED MOUSE MODELS MARKET, BY REGION, 2021–2028 (USD MILLION)
TABLE 12 NORTH AMERICA: HUMANIZED MOUSE MODELS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 13 EUROPE: HUMANIZED MOUSE MODELS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 14 ASIA PACIFIC: HUMANIZED MOUSE MODELS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
6.2.1 GENETIC HUMANIZED MOUSE MODELS
6.2.1.1 Advancements in genetic engineering technologies to drive market
TABLE 15 GENETIC HUMANIZED MOUSE MODELS MARKET, BY REGION, 2021–2028 (USD MILLION)
TABLE 16 NORTH AMERICA: GENETIC HUMANIZED MOUSE MODELS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 17 EUROPE: GENETIC HUMANIZED MOUSE MODELS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 18 ASIA PACIFIC: GENETIC HUMANIZED MOUSE MODELS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
6.2.2 CELL-BASED HUMANIZED MOUSE MODELS
TABLE 19 CELL-BASED HUMANIZED MOUSE MODELS MARKET, BY REGION, 2021–2028 (USD MILLION)
TABLE 20 NORTH AMERICA: CELL-BASED HUMANIZED MOUSE MODELS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 21 EUROPE: CELL-BASED HUMANIZED MOUSE MODELS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 22 ASIA PACIFIC: CELL-BASED HUMANIZED MOUSE MODELS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
6.2.2.1 CD34 humanized mouse models
6.2.2.1.1 Rising demand for stem cell therapy to propel market
TABLE 23 CD34 HUMANIZED MODELS MARKET, BY REGION, 2021–2028 (USD MILLION)
TABLE 24 NORTH AMERICA: CD34 HUMANIZED MODELS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 25 EUROPE: CD34 HUMANIZED MODELS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 26 ASIA PACIFIC: CD34 HUMANIZED MODELS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
6.2.2.2 PBMC humanized mouse models
6.2.2.2.1 Growing prevalence of infectious diseases to fuel uptake
TABLE 27 PBMC HUMANIZED MICE MODELS MARKET, BY REGION, 2021–2028 (USD MILLION)
TABLE 28 NORTH AMERICA: PBMC HUMANIZED MICE MODELS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 29 EUROPE: PBMC HUMANIZED MICE MODELS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 30 ASIA PACIFIC: PBMC HUMANIZED MICE MODELS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
6.2.2.3 BLT humanized mouse models
6.2.2.3.1 Increasing HIV cases to propel market
TABLE 31 BLT HUMANIZED MOUSE MODELS MARKET, BY REGION, 2021–2028 (USD MILLION)
TABLE 32 NORTH AMERICA: BLT HUMANIZED MOUSE MODELS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 33 EUROPE: BLT HUMANIZED MOUSE MODELS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 34 ASIA PACIFIC: BLT HUMANIZED MOUSE MODELS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
6.3 HUMANIZED RAT MODELS
6.3.1 ABILITY TO SUSTAIN HIGH INTRAVENOUS DOSING TO SUPPORT MARKET GROWTH
TABLE 35 HUMANIZED RAT MODELS MARKET, BY REGION, 2021–2028 (USD MILLION)
TABLE 36 NORTH AMERICA: HUMANIZED RAT MODELS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 37 EUROPE: HUMANIZED RAT MODELS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 38 ASIA PACIFIC: HUMANIZED RAT MODELS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
7 HUMANIZED MOUSE AND RAT MODEL MARKET, BY APPLICATION
7.1 INTRODUCTION
TABLE 39 HUMANIZED MOUSE AND RAT MODEL MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
7.2 ONCOLOGY
7.2.1 UTILIZATION OF MOUSE MODELS IN CANCER RESEARCH TO PROPEL MARKET
TABLE 40 HUMANIZED MOUSE AND RAT MODEL MARKET FOR ONCOLOGY, BY REGION, 2021–2028 (USD MILLION)
TABLE 41 NORTH AMERICA: HUMANIZED MOUSE AND RAT MODEL MARKET FOR ONCOLOGY, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 42 EUROPE: HUMANIZED MOUSE AND RAT MODEL MARKET FOR ONCOLOGY, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 43 ASIA PACIFIC: HUMANIZED MOUSE AND RAT MODEL MARKET FOR ONCOLOGY, BY COUNTRY, 2021–2028 (USD MILLION)
7.3 IMMUNOLOGY AND INFECTIOUS DISEASES
7.3.1 DEVELOPMENT OF ADVANCED MODELS FOR TREATMENT OF RARE DISEASES TO DRIVE MARKET
TABLE 44 HUMANIZED MOUSE AND RAT MODEL MARKET FOR IMMUNOLOGY AND INFECTIOUS DISEASES, BY REGION, 2021–2028 (USD MILLION)
TABLE 45 NORTH AMERICA: HUMANIZED MOUSE AND RAT MODEL MARKET FOR IMMUNOLOGY AND INFECTIOUS DISEASES, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 46 EUROPE: HUMANIZED MOUSE AND RAT MODEL MARKET FOR IMMUNOLOGY AND INFECTIOUS DISEASES, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 47 ASIA PACIFIC: HUMANIZED MOUSE AND RAT MODEL MARKET FOR IMMUNOLOGY AND INFECTIOUS DISEASES, BY COUNTRY, 2021–2028 (USD MILLION)
7.4 NEUROSCIENCE
7.4.1 RISING INCIDENCE OF CNS DISORDERS TO PROPEL MARKET
TABLE 48 HUMANIZED MOUSE AND RAT MODEL MARKET FOR NEUROSCIENCE, BY REGION, 2021–2028 (USD MILLION)
TABLE 49 NORTH AMERICA: HUMANIZED MOUSE AND RAT MODEL MARKET FOR NEUROSCIENCE, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 50 EUROPE: HUMANIZED MOUSE AND RAT MODEL MARKET FOR NEUROSCIENCE, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 51 ASIA PACIFIC: HUMANIZED MOUSE AND RAT MODEL MARKET FOR NEUROSCIENCE, BY COUNTRY, 2021–2028 (USD MILLION)
7.5 TOXICOLOGY
7.5.1 INCREASING CLINICAL TRIALS FOR TOXICOLOGY STUDIES TO SUPPORT MARKET GROWTH
TABLE 52 HUMANIZED MOUSE AND RAT MODEL MARKET FOR TOXICOLOGY, BY REGION, 2021–2028 (USD MILLION)
TABLE 53 NORTH AMERICA: HUMANIZED MOUSE AND RAT MODEL MARKET FOR TOXICOLOGY, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 54 EUROPE: HUMANIZED MOUSE AND RAT MODEL MARKET FOR TOXICOLOGY, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 55 ASIA PACIFIC: HUMANIZED MOUSE AND RAT MODEL MARKET FOR TOXICOLOGY, BY COUNTRY, 2021–2028 (USD MILLION)
7.6 HEMATOPOIESIS
7.6.1 RISING DEMAND FOR STEM CELL THERAPY TO DRIVE MARKET
TABLE 56 HUMANIZED MOUSE AND RAT MODEL MARKET FOR HEMATOPOIESIS, BY REGION, 2021–2028 (USD MILLION)
TABLE 57 NORTH AMERICA: HUMANIZED MOUSE AND RAT MODEL MARKET FOR HEMATOPOIESIS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 58 EUROPE: HUMANIZED MOUSE AND RAT MODEL MARKET FOR HEMATOPOIESIS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 59 ASIA PACIFIC: HUMANIZED MOUSE AND RAT MODEL MARKET FOR HEMATOPOIESIS, BY COUNTRY, 2021–2028 (USD MILLION)
7.7 OTHER APPLICATIONS
TABLE 60 HUMANIZED MOUSE AND RAT MODEL MARKET FOR OTHER APPLICATIONS, BY REGION, 2021–2028 (USD MILLION)
TABLE 61 NORTH AMERICA: HUMANIZED MOUSE AND RAT MODEL MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 62 EUROPE: HUMANIZED MOUSE AND RAT MODEL MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 63 ASIA PACIFIC: HUMANIZED MOUSE AND RAT MODEL MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2021–2028 (USD MILLION)
8 HUMANIZED MOUSE AND RAT MODEL MARKET, BY END USER
8.1 INTRODUCTION
TABLE 64 HUMANIZED MOUSE AND RAT MODEL MARKET, BY END USER, 2021–2028 (USD MILLION)
8.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
8.2.1 INCREASING EXPENDITURE ON R&D FOR DRUG DEVELOPMENT TO DRIVE MARKET
TABLE 65 HUMANIZED MOUSE AND RAT MODEL MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2021–2028 (USD MILLION)
TABLE 66 NORTH AMERICA: HUMANIZED MOUSE AND RAT MODEL MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 67 EUROPE: HUMANIZED MOUSE AND RAT MODEL MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 68 ASIA PACIFIC: HUMANIZED MOUSE AND RAT MODEL MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2021–2028 (USD MILLION)
8.3 CONTRACT RESEARCH ORGANIZATIONS AND CONTRACT DEVELOPMENT MANUFACTURING ORGANIZATIONS
8.3.1 RISING OUTSOURCING OF DRUG DISCOVERY SERVICES BY PHARMA & BIOTECH COMPANIES TO PROPEL MARKET
TABLE 69 HUMANIZED MOUSE AND RAT MODEL MARKET FOR CROS AND CDMOS, BY REGION, 2021–2028 (USD MILLION)
TABLE 70 NORTH AMERICA: HUMANIZED MOUSE AND RAT MODEL MARKET FOR CROS AND CDMOS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 71 EUROPE: HUMANIZED MOUSE AND RAT MODEL MARKET FOR CROS AND CDMOS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 72 ASIA PACIFIC: HUMANIZED MOUSE AND RAT MODEL MARKET FOR CROS AND CDMOS, BY COUNTRY, 2021–2028 (USD MILLION)
8.4 ACADEMIC & RESEARCH INSTITUTES
8.4.1 SUPPORTIVE FUNDING INVESTMENTS FOR LIFE SCIENCE RESEARCH TO SUPPORT MARKET GROWTH
TABLE 73 HUMANIZED MOUSE AND RAT MODEL MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2021–2028 (USD MILLION)
TABLE 74 NORTH AMERICA: HUMANIZED MOUSE AND RAT MODEL MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 75 EUROPE: HUMANIZED MOUSE AND RAT MODEL MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 76 ASIA PACIFIC: HUMANIZED MOUSE AND RAT MODEL MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2021–2028 (USD MILLION)
9 HUMANIZED MOUSE AND RAT MODEL MARKET, BY REGION
9.1 INTRODUCTION
TABLE 77 HUMANIZED MOUSE AND RAT MODEL MARKET, BY REGION, 2021–2028 (USD MILLION)
9.2 NORTH AMERICA
FIGURE 20 HUMANIZED MOUSE AND RAT MODEL MARKET: NORTH AMERICA SNAPSHOT
TABLE 78 NORTH AMERICA: HUMANIZED MOUSE AND RAT MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 79 NORTH AMERICA: HUMANIZED MOUSE AND RAT MODEL MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 80 NORTH AMERICA: HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 81 NORTH AMERICA: CELL-BASED HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 82 NORTH AMERICA: HUMANIZED MOUSE AND RAT MODEL MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 83 NORTH AMERICA: HUMANIZED MOUSE AND RAT MODEL MARKET, BY END USER, 2021–2028 (USD MILLION)
9.2.1 US
9.2.1.1 Growing research initiatives on mAbs and biosimilars to drive market
TABLE 84 US: HUMANIZED MOUSE AND RAT MODEL MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 85 US: HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 86 US: CELL-BASED HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 87 US: HUMANIZED MOUSE AND RAT MODEL MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 88 US: HUMANIZED MOUSE AND RAT MODEL MARKET, BY END USER, 2021–2028 (USD MILLION)
9.2.2 CANADA
9.2.2.1 Government initiatives on stem cell research to drive market
TABLE 89 CANADA: HUMANIZED MOUSE AND RAT MODEL MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 90 CANADA: HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 91 CANADA: CELL-BASED HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 92 CANADA: HUMANIZED MOUSE AND RAT MODEL MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 93 CANADA: HUMANIZED MOUSE AND RAT MODEL MARKET, BY END USER, 2021–2028 (USD MILLION)
9.2.3 NORTH AMERICA: RECESSION IMPACT
9.3 EUROPE
TABLE 94 EUROPE: HUMANIZED MOUSE AND RAT MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 95 EUROPE: HUMANIZED MOUSE AND RAT MODEL MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 96 EUROPE: HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 97 EUROPE: CELL-BASED HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 98 EUROPE: HUMANIZED MOUSE AND RAT MODEL MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 99 EUROPE: HUMANIZED MOUSE AND RAT MODEL MARKET, BY END USER, 2021–2028 (USD MILLION)
9.3.1 GERMANY
9.3.1.1 Rising pharmaceutical R&D expenditure to drive market
TABLE 100 GERMANY: HUMANIZED MOUSE AND RAT MODEL MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 101 GERMANY: HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 102 GERMANY: CELL-BASED HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 103 GERMANY: HUMANIZED MOUSE AND RAT MODEL MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 104 GERMANY: HUMANIZED MOUSE AND RAT MODEL MARKET, BY END USER, 2021–2028 (USD MILLION)
9.3.2 UK
9.3.2.1 Growing investments in cancer research to drive market
TABLE 105 UK: HUMANIZED MOUSE AND RAT MODEL MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 106 UK: HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 107 UK: CELL-BASED HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 108 UK: HUMANIZED MOUSE AND RAT MODEL MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 109 UK: HUMANIZED MOUSE AND RAT MODEL MARKET, BY END USER, 2021–2028 (USD MILLION)
9.3.3 FRANCE
9.3.3.1 Increasing initiatives for genomics research to support market growth
TABLE 110 FRANCE: HUMANIZED MOUSE AND RAT MODEL MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 111 FRANCE: HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 112 FRANCE: CELL-BASED HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 113 FRANCE: HUMANIZED MOUSE AND RAT MODEL MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 114 FRANCE: HUMANIZED MOUSE AND RAT MODEL MARKET, BY END USER, 2021–2028 (USD MILLION)
9.3.4 ITALY
9.3.4.1 Rising R&D spending on pharmaceutical production to fuel market
TABLE 115 ITALY: HUMANIZED MOUSE AND RAT MODEL MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 116 ITALY: HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 117 ITALY: CELL-BASED HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 118 ITALY: HUMANIZED MOUSE AND RAT MODEL MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 119 ITALY: HUMANIZED MOUSE AND RAT MODEL MARKET, BY END USER, 2021–2028 (USD MILLION)
9.3.5 SPAIN
9.3.5.1 Rising growth in biotech industry to drive market
TABLE 120 SPAIN: HUMANIZED MOUSE AND RAT MODEL MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 121 SPAIN: HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 122 SPAIN: CELL-BASED HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 123 SPAIN: HUMANIZED MOUSE AND RAT MODEL MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 124 SPAIN: HUMANIZED MOUSE AND RAT MODEL MARKET, BY END USER, 2021–2028 (USD MILLION)
9.3.6 REST OF EUROPE
TABLE 125 REST OF EUROPE: HUMANIZED MOUSE AND RAT MODEL MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 126 REST OF EUROPE: HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 127 REST OF EUROPE: CELL-BASED HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 128 REST OF EUROPE: HUMANIZED MOUSE AND RAT MODEL MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 129 REST OF EUROPE: HUMANIZED MOUSE AND RAT MODEL MARKET, BY END USER, 2021–2028 (USD MILLION)
9.3.7 EUROPE: RECESSION IMPACT
9.4 ASIA PACIFIC
FIGURE 21 HUMANIZED MOUSE AND RAT MODEL MARKET: ASIA PACIFIC SNAPSHOT
TABLE 130 ASIA PACIFIC: HUMANIZED MOUSE AND RAT MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 131 ASIA PACIFIC: HUMANIZED MOUSE AND RAT MODEL MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 132 ASIA PACIFIC: HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 133 ASIA PACIFIC: CELL-BASED HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 134 ASIA PACIFIC: HUMANIZED MOUSE AND RAT MODEL MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 135 ASIA PACIFIC: HUMANIZED MOUSE AND RAT MODEL MARKET, BY END USER, 2021–2028 (USD MILLION)
9.4.1 CHINA
9.4.1.1 High growth in pharmaceutical industry to drive market
TABLE 136 CHINA: HUMANIZED MOUSE AND RAT MODEL MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 137 CHINA: HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 138 CHINA: CELL-BASED HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 139 CHINA: HUMANIZED MOUSE AND RAT MODEL MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 140 CHINA: HUMANIZED MOUSE AND RAT MODEL MARKET, BY END USER, 2021–2028 (USD MILLION)
9.4.2 JAPAN
9.4.2.1 Growing research collaborations among pharmaceutical companies to drive market
TABLE 141 JAPAN: HUMANIZED MOUSE AND RAT MODEL MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 142 JAPAN: HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 143 JAPAN: CELL-BASED HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 144 JAPAN: HUMANIZED MOUSE AND RAT MODEL MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 145 JAPAN: HUMANIZED MOUSE AND RAT MODEL MARKET, BY END USER, 2021–2028 (USD MILLION)
9.4.3 INDIA
9.4.3.1 Growth in biotech industry to drive market
TABLE 146 INDIA: HUMANIZED MOUSE AND RAT MODEL MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 147 INDIA: HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 148 INDIA: CELL-BASED HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 149 INDIA: HUMANIZED MOUSE AND RAT MODEL MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 150 INDIA: HUMANIZED MOUSE AND RAT MODEL MARKET, BY END USER, 2021–2028 (USD MILLION)
9.4.4 SOUTH KOREA
9.4.4.1 Rising government-funded investments for pharmaceutical R&D to drive market
TABLE 151 SOUTH KOREA: HUMANIZED MOUSE AND RAT MODEL MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 152 SOUTH KOREA: HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 153 SOUTH KOREA: CELL-BASED HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 154 SOUTH KOREA: HUMANIZED MOUSE AND RAT MODEL MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 155 SOUTH KOREA: HUMANIZED MOUSE AND RAT MODEL MARKET, BY END USER, 2021–2028 (USD MILLION)
9.4.5 REST OF ASIA PACIFIC
TABLE 156 REST OF ASIA PACIFIC: HUMANIZED MOUSE AND RAT MODEL MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 157 REST OF ASIA PACIFIC: HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 158 REST OF ASIA PACIFIC: CELL-BASED HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 159 REST OF ASIA PACIFIC: HUMANIZED MOUSE AND RAT MODEL MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 160 REST OF ASIA PACIFIC: HUMANIZED MOUSE AND RAT MODEL MARKET, BY END USER, 2021–2028 (USD MILLION)
9.4.6 ASIA PACIFIC: RECESSION IMPACT
9.5 LATIN AMERICA
9.5.1 GROWING PRESENCE OF PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES TO PROPEL MARKET
TABLE 161 LATIN AMERICA: HUMANIZED MOUSE AND RAT MODEL MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 162 LATIN AMERICA: HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 163 LATIN AMERICA: CELL-BASED HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 164 LATIN AMERICA: HUMANIZED MOUSE AND RAT MODEL MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 165 LATIN AMERICA: HUMANIZED MOUSE AND RAT MODEL MARKET, BY END USER, 2021–2028 (USD MILLION)
9.5.2 LATIN AMERICA: RECESSION IMPACT
9.6 MIDDLE EAST & AFRICA
9.6.1 RISING INITIATIVES FOR CLINICAL TESTING TO SUPPORT MARKET GROWTH
TABLE 166 MIDDLE EAST & AFRICA: HUMANIZED MOUSE AND RAT MODEL MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 167 MIDDLE EAST & AFRICA: HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 168 MIDDLE EAST & AFRICA: CELL-BASED HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 169 MIDDLE EAST & AFRICA: HUMANIZED MOUSE AND RAT MODEL MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 170 MIDDLE EAST & AFRICA: HUMANIZED MOUSE AND RAT MODEL MARKET, BY END USER, 2021–2028 (USD MILLION)
9.6.2 MIDDLE EAST & AFRICA: RECESSION IMPACT
10 COMPETITIVE LANDSCAPE
10.1 OVERVIEW
10.2 STRATEGIES ADOPTED BY KEY PLAYERS
FIGURE 22 HUMANIZED MOUSE AND RAT MODEL MARKET: KEY STRATEGIES ADOPTED BY MARKET PLAYERS (2019?2023)
10.3 MARKET SHARE ANALYSIS
FIGURE 23 HUMANIZED MOUSE AND RAT MODEL MARKET SHARE FOR KEY PLAYERS (2022)
TABLE 171 HUMANIZED MOUSE AND RAT MODEL MARKET: INTENSITY OF COMPETITIVE RIVALRY
10.4 COMPANY EVALUATION MATRIX
10.4.1 STARS
10.4.2 EMERGING LEADERS
10.4.3 PERVASIVE PLAYERS
10.4.4 PARTICIPANTS
FIGURE 24 HUMANIZED MOUSE AND RAT MODEL MARKET: COMPANY EVALUATION MATRIX OF LEADING PLAYERS (2022)
10.5 COMPANY EVALUATION MATRIX FOR STARTUPS/SMES
10.5.1 PROGRESSIVE COMPANIES
10.5.2 STARTING BLOCKS
10.5.3 RESPONSIVE COMPANIES
10.5.4 DYNAMIC COMPANIES
10.6 HUMANIZED MOUSE AND RAT MODEL MARKET: FOOTPRINT ANALYSIS OF COMPANIES
TABLE 172 HUMANIZED MOUSE AND RAT MODEL MARKET: PRODUCT FOOTPRINT ANALYSIS (2022)
TABLE 173 HUMANIZED MOUSE AND RAT MODEL MARKET: END-USER FOOTPRINT ANALYSIS
TABLE 174 HUMANIZED MOUSE AND RAT MODEL MARKET: REGIONAL FOOTPRINT ANALYSIS (2022)
10.7 COMPETITIVE SCENARIO AND TRENDS
TABLE 175 HUMANIZED MOUSE AND RAT MODEL MARKET: PRODUCT LAUNCHES
TABLE 176 HUMANIZED MOUSE AND RAT MODEL MARKET: DEALS
11 COMPANY PROFILES
11.1 KEY PLAYERS
(Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats))*
11.1.1 CHARLES RIVER LABORATORIES
TABLE 177 CHARLES RIVER LABORATORIES: BUSINESS OVERVIEW
FIGURE 26 CHARLES RIVER LABORATORIES: COMPANY SNAPSHOT (2022)
11.1.2 THE JACKSON LABORATORY
TABLE 178 THE JACKSON LABORATORY: BUSINESS OVERVIEW
FIGURE 27 THE JACKSON LABORATORY: COMPANY SNAPSHOT (2022)
11.1.3 INOTIV
TABLE 179 INOTIV: COMPANY OVERVIEW
FIGURE 28 INOTIV: COMPANY SNAPSHOT
11.1.4 TACONIC BIOSCIENCES, INC.
TABLE 180 TACONIC BIOSCIENCES, INC.: BUSINESS OVERVIEW
11.1.5 CROWN BIOSCIENCE
TABLE 181 CROWN BIOSCIENCE: BUSINESS OVERVIEW
11.1.6 CHAMPIONS ONCOLOGY, INC.
TABLE 182 CHAMPIONS ONCOLOGY, INC.: BUSINESS OVERVIEW
FIGURE 29 CHAMPIONS ONCOLOGY, INC.: COMPANY SNAPSHOT (2022)
11.1.7 HERA BIOLABS
TABLE 183 HERA BIOLABS: BUSINESS OVERVIEW
11.1.8 GENOWAY
TABLE 184 GENOWAY: BUSINESS OVERVIEW
11.1.9 VITALSTAR BIOTECHNOLOGY
TABLE 185 VITALSTAR BIOTECHNOLOGY: BUSINESS OVERVIEW
11.1.10 INGENIOUS TARGETING LABORATORY
TABLE 186 INGENIOUS TARGETING LABORATORY: BUSINESS OVERVIEW
11.1.11 TRANS GENIC
TABLE 187 TRANS GENIC: BUSINESS OVERVIEW
FIGURE 30 TRANS GENIC: COMPANY SNAPSHOT
11.1.12 HARBOUR ANTIBODIES BV (A SUBSIDIARY OF HARBOUR BIOMED)
TABLE 188 HARBOUR ANTIBODIES BV: BUSINESS OVERVIEW
FIGURE 31 HARBOUR BIOMED: COMPANY SNAPSHOT
11.1.13 ONCODESIGN
TABLE 189 ONCODESIGN: BUSINESS OVERVIEW
11.1.14 PHARMATEST SERVICES
TABLE 190 PHARMATEST SERVICES: BUSINESS OVERVIEW
11.2 OTHER PLAYERS
11.2.1 OZGENE PTY LTD.
11.2.2 TRANSCURE BIOSERVICES
11.2.3 CYAGEN BIOSCIENCES
11.2.4 ARAGEN LIFE SCIENCES LTD. (FORMERLY GVK BIO)
11.2.5 BIOCYTOGEN
11.2.6 GEMPHARMATECH
*Details on Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats) might not be captured in case of unlisted companies.
12 APPENDIX
12.1 DISCUSSION GUIDE
12.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
12.3 CUSTOMIZATION OPTIONS
12.4 RELATED REPORTS
12.5 AUTHOR DETAILS
1.1 STUDY OBJECTIVES
1.2 MARKET DEFINITION
1.2.1 INCLUSIONS AND EXCLUSIONS
1.3 MARKET SCOPE
1.3.1 MARKETS COVERED
1.3.2 YEARS CONSIDERED
1.4 CURRENCY CONSIDERED
1.5 LIMITATIONS
1.6 STAKEHOLDERS
1.7 SUMMARY OF CHANGES
2 RESEARCH METHODOLOGY
2.1 RESEARCH APPROACH
FIGURE 1 RESEARCH DESIGN
2.1.1 SECONDARY DATA
2.1.2 PRIMARY DATA
2.1.2.1 Breakdown of primary sources
FIGURE 2 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
2.2 PRIMARY INSIGHTS
2.3 MARKET SIZE ESTIMATION
FIGURE 3 HUMANIZED MOUSE AND RAT MODEL MARKET: MARKET SIZE ESTIMATION (SUPPLY-SIDE ANALYSIS)
FIGURE 4 MARKET SIZE ESTIMATION: APPROACH 1 (COMPANY REVENUE ANALYSIS-BASED ESTIMATION)
2.4 MARKET GROWTH RATE PROJECTIONS
FIGURE 5 HUMANIZED MOUSE AND RAT MODEL MARKET: CAGR PROJECTIONS
FIGURE 6 HUMANIZED MOUSE AND RAT MODEL MARKET: CAGR PROJECTIONS FROM ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
2.4.1 DATA TRIANGULATION AND MARKET BREAKDOWN
FIGURE 7 DATA TRIANGULATION METHODOLOGY
2.5 RESEARCH ASSUMPTIONS
2.6 RISK IMPACT ANALYSIS
2.7 RECESSION IMPACT ANALYSIS
TABLE 1 GLOBAL INFLATION RATE PROJECTIONS, 2024–2028 (% GROWTH)
TABLE 2 US HEALTH EXPENDITURE, 2019–2022 (USD MILLION)
TABLE 3 US HEALTH EXPENDITURE, 2023–2027 (USD MILLION)
3 EXECUTIVE SUMMARY
FIGURE 8 HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2023 VS. 2028 (USD MILLION)
FIGURE 9 HUMANIZED MOUSE AND RAT MODEL MARKET, BY APPLICATION, 2023 VS. 2028 (USD MILLION)
FIGURE 10 HUMANIZED MOUSE AND RAT MODEL MARKET, BY END USER, 2023 VS. 2028 (USD MILLION)
FIGURE 11 GEOGRAPHICAL SNAPSHOT OF HUMANIZED MOUSE AND RAT MODEL MARKET
4 PREMIUM INSIGHTS
4.1 HUMANIZED MOUSE AND RAT MODEL MARKET OVERVIEW
FIGURE 12 RISING USE OF HUMANIZED MODELS IN DRUG DISCOVERY RESEARCH TO DRIVE MARKET
4.2 ASIA PACIFIC: HUMANIZED MOUSE AND RAT MODEL MARKET, BY END USER AND COUNTRY
FIGURE 13 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES SEGMENT ACCOUNTED FOR LARGEST MARKET SHARE IN CHINA FOR 2022
4.3 NORTH AMERICA: CELL-BASED HUMANIZED MOUSE MODELS MARKET, BY TYPE (USD MILLION)
FIGURE 14 PBMC HUMANIZED MOUSE MODELS SEGMENT TO REGISTER HIGHER GROWTH RATE DURING FORECAST PERIOD
5 MARKET OVERVIEW
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
FIGURE 15 HUMANIZED MOUSE AND RAT MODEL MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
5.2.1 DRIVERS
5.2.1.1 Rising use of humanized models in drug discovery research
5.2.1.2 Growing preference for personalized medicine
5.2.1.3 Government-funded initiatives for cancer research
5.2.1.4 Increasing R&D activities in pharmaceutical & biotechnology industries
TABLE 4 NUMBER OF R&D PRODUCTS, BY INDICATION (2022)
5.2.2 RESTRAINTS
5.2.2.1 High cost of custom humanized models
5.2.2.2 Stringent regulatory compliance for ethical use of animal models
5.2.3 OPPORTUNITIES
5.2.3.1 Growing preference for humanized PDX models
5.2.3.2 Emergence of CRISPR in biomedical research
5.2.3.3 Rising demand for humanized rat models
5.2.4 CHALLENGES
5.2.4.1 Alternative methods for animal testing
5.2.4.2 Limitations of humanized mouse models
5.3 REGULATORY ANALYSIS
5.3.1 NORTH AMERICA
5.3.2 EUROPE
5.3.3 ASIA PACIFIC
5.3.3.1 China
5.3.3.2 Japan
5.3.3.3 India
5.3.3.4 Australia
5.3.4 LATIN AMERICA
5.3.5 MIDDLE EAST & AFRICA
5.4 PRICING ANALYSIS
TABLE 5 PRICE OF HUMANIZED MOUSE MODELS (2022)
5.5 TECHNOLOGY ANALYSIS
5.6 VALUE CHAIN ANALYSIS
FIGURE 16 CREATION OF HUMANIZED MODELS—MAXIMUM VALUE IS ADDED DURING IMPLANTATION OF GRAFT/TUMOR CELLS IN IMMUNODEFICIENT MICE OR RATS
5.7 ECOSYSTEM ANALYSIS
FIGURE 17 HUMANIZED MOUSE AND RAT MODEL MARKET: ECOSYSTEM MAP
TABLE 6 SUPPLY CHAIN ECOSYSTEM
5.8 PORTER’S FIVE FORCES ANALYSIS
TABLE 7 HUMANIZED MOUSE AND RAT MODEL MARKET: PORTER’S FIVE FORCES ANALYSIS
5.8.1 THREAT OF NEW ENTRANTS
5.8.2 THREAT OF SUBSTITUTES
5.8.3 BARGAINING POWER OF BUYERS
5.8.4 BARGAINING POWER OF SUPPLIERS
5.8.5 INTENSITY OF COMPETITIVE RIVALRY
5.9 PATENT ANALYSIS
5.10 KEY CONFERENCES AND EVENTS
5.10.1 HUMANIZED MOUSE AND RAT MODEL MARKET: KEY CONFERENCES AND EVENTS IN 2023
TABLE 8 HUMANIZED MOUSE AND RAT MODEL MARKET: KEY CONFERENCES AND EVENTS IN 2023
5.11 KEY STAKEHOLDERS AND BUYING CRITERIA
5.11.1 KEY STAKEHOLDERS IN BUYING PROCESS
FIGURE 18 HUMANIZED MOUSE AND RAT MODEL MARKET: INFLUENCE OF KEY STAKEHOLDERS ON BUYING PROCESS
5.11.2 HUMANIZED MOUSE AND RAT MODEL MARKET: KEY BUYING CRITERIA
FIGURE 19 KEY BUYING CRITERIA FOR END USERS
6 HUMANIZED MOUSE AND RAT MODEL MARKET, BY TYPE
6.1 INTRODUCTION
TABLE 9 HUMANIZED MOUSE AND RAT MODEL MARKET, BY TYPE, 2021–2028 (USD MILLION)
6.2 HUMANIZED MOUSE MODELS
TABLE 10 HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 11 HUMANIZED MOUSE MODELS MARKET, BY REGION, 2021–2028 (USD MILLION)
TABLE 12 NORTH AMERICA: HUMANIZED MOUSE MODELS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 13 EUROPE: HUMANIZED MOUSE MODELS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 14 ASIA PACIFIC: HUMANIZED MOUSE MODELS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
6.2.1 GENETIC HUMANIZED MOUSE MODELS
6.2.1.1 Advancements in genetic engineering technologies to drive market
TABLE 15 GENETIC HUMANIZED MOUSE MODELS MARKET, BY REGION, 2021–2028 (USD MILLION)
TABLE 16 NORTH AMERICA: GENETIC HUMANIZED MOUSE MODELS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 17 EUROPE: GENETIC HUMANIZED MOUSE MODELS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 18 ASIA PACIFIC: GENETIC HUMANIZED MOUSE MODELS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
6.2.2 CELL-BASED HUMANIZED MOUSE MODELS
TABLE 19 CELL-BASED HUMANIZED MOUSE MODELS MARKET, BY REGION, 2021–2028 (USD MILLION)
TABLE 20 NORTH AMERICA: CELL-BASED HUMANIZED MOUSE MODELS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 21 EUROPE: CELL-BASED HUMANIZED MOUSE MODELS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 22 ASIA PACIFIC: CELL-BASED HUMANIZED MOUSE MODELS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
6.2.2.1 CD34 humanized mouse models
6.2.2.1.1 Rising demand for stem cell therapy to propel market
TABLE 23 CD34 HUMANIZED MODELS MARKET, BY REGION, 2021–2028 (USD MILLION)
TABLE 24 NORTH AMERICA: CD34 HUMANIZED MODELS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 25 EUROPE: CD34 HUMANIZED MODELS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 26 ASIA PACIFIC: CD34 HUMANIZED MODELS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
6.2.2.2 PBMC humanized mouse models
6.2.2.2.1 Growing prevalence of infectious diseases to fuel uptake
TABLE 27 PBMC HUMANIZED MICE MODELS MARKET, BY REGION, 2021–2028 (USD MILLION)
TABLE 28 NORTH AMERICA: PBMC HUMANIZED MICE MODELS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 29 EUROPE: PBMC HUMANIZED MICE MODELS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 30 ASIA PACIFIC: PBMC HUMANIZED MICE MODELS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
6.2.2.3 BLT humanized mouse models
6.2.2.3.1 Increasing HIV cases to propel market
TABLE 31 BLT HUMANIZED MOUSE MODELS MARKET, BY REGION, 2021–2028 (USD MILLION)
TABLE 32 NORTH AMERICA: BLT HUMANIZED MOUSE MODELS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 33 EUROPE: BLT HUMANIZED MOUSE MODELS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 34 ASIA PACIFIC: BLT HUMANIZED MOUSE MODELS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
6.3 HUMANIZED RAT MODELS
6.3.1 ABILITY TO SUSTAIN HIGH INTRAVENOUS DOSING TO SUPPORT MARKET GROWTH
TABLE 35 HUMANIZED RAT MODELS MARKET, BY REGION, 2021–2028 (USD MILLION)
TABLE 36 NORTH AMERICA: HUMANIZED RAT MODELS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 37 EUROPE: HUMANIZED RAT MODELS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 38 ASIA PACIFIC: HUMANIZED RAT MODELS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
7 HUMANIZED MOUSE AND RAT MODEL MARKET, BY APPLICATION
7.1 INTRODUCTION
TABLE 39 HUMANIZED MOUSE AND RAT MODEL MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
7.2 ONCOLOGY
7.2.1 UTILIZATION OF MOUSE MODELS IN CANCER RESEARCH TO PROPEL MARKET
TABLE 40 HUMANIZED MOUSE AND RAT MODEL MARKET FOR ONCOLOGY, BY REGION, 2021–2028 (USD MILLION)
TABLE 41 NORTH AMERICA: HUMANIZED MOUSE AND RAT MODEL MARKET FOR ONCOLOGY, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 42 EUROPE: HUMANIZED MOUSE AND RAT MODEL MARKET FOR ONCOLOGY, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 43 ASIA PACIFIC: HUMANIZED MOUSE AND RAT MODEL MARKET FOR ONCOLOGY, BY COUNTRY, 2021–2028 (USD MILLION)
7.3 IMMUNOLOGY AND INFECTIOUS DISEASES
7.3.1 DEVELOPMENT OF ADVANCED MODELS FOR TREATMENT OF RARE DISEASES TO DRIVE MARKET
TABLE 44 HUMANIZED MOUSE AND RAT MODEL MARKET FOR IMMUNOLOGY AND INFECTIOUS DISEASES, BY REGION, 2021–2028 (USD MILLION)
TABLE 45 NORTH AMERICA: HUMANIZED MOUSE AND RAT MODEL MARKET FOR IMMUNOLOGY AND INFECTIOUS DISEASES, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 46 EUROPE: HUMANIZED MOUSE AND RAT MODEL MARKET FOR IMMUNOLOGY AND INFECTIOUS DISEASES, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 47 ASIA PACIFIC: HUMANIZED MOUSE AND RAT MODEL MARKET FOR IMMUNOLOGY AND INFECTIOUS DISEASES, BY COUNTRY, 2021–2028 (USD MILLION)
7.4 NEUROSCIENCE
7.4.1 RISING INCIDENCE OF CNS DISORDERS TO PROPEL MARKET
TABLE 48 HUMANIZED MOUSE AND RAT MODEL MARKET FOR NEUROSCIENCE, BY REGION, 2021–2028 (USD MILLION)
TABLE 49 NORTH AMERICA: HUMANIZED MOUSE AND RAT MODEL MARKET FOR NEUROSCIENCE, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 50 EUROPE: HUMANIZED MOUSE AND RAT MODEL MARKET FOR NEUROSCIENCE, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 51 ASIA PACIFIC: HUMANIZED MOUSE AND RAT MODEL MARKET FOR NEUROSCIENCE, BY COUNTRY, 2021–2028 (USD MILLION)
7.5 TOXICOLOGY
7.5.1 INCREASING CLINICAL TRIALS FOR TOXICOLOGY STUDIES TO SUPPORT MARKET GROWTH
TABLE 52 HUMANIZED MOUSE AND RAT MODEL MARKET FOR TOXICOLOGY, BY REGION, 2021–2028 (USD MILLION)
TABLE 53 NORTH AMERICA: HUMANIZED MOUSE AND RAT MODEL MARKET FOR TOXICOLOGY, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 54 EUROPE: HUMANIZED MOUSE AND RAT MODEL MARKET FOR TOXICOLOGY, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 55 ASIA PACIFIC: HUMANIZED MOUSE AND RAT MODEL MARKET FOR TOXICOLOGY, BY COUNTRY, 2021–2028 (USD MILLION)
7.6 HEMATOPOIESIS
7.6.1 RISING DEMAND FOR STEM CELL THERAPY TO DRIVE MARKET
TABLE 56 HUMANIZED MOUSE AND RAT MODEL MARKET FOR HEMATOPOIESIS, BY REGION, 2021–2028 (USD MILLION)
TABLE 57 NORTH AMERICA: HUMANIZED MOUSE AND RAT MODEL MARKET FOR HEMATOPOIESIS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 58 EUROPE: HUMANIZED MOUSE AND RAT MODEL MARKET FOR HEMATOPOIESIS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 59 ASIA PACIFIC: HUMANIZED MOUSE AND RAT MODEL MARKET FOR HEMATOPOIESIS, BY COUNTRY, 2021–2028 (USD MILLION)
7.7 OTHER APPLICATIONS
TABLE 60 HUMANIZED MOUSE AND RAT MODEL MARKET FOR OTHER APPLICATIONS, BY REGION, 2021–2028 (USD MILLION)
TABLE 61 NORTH AMERICA: HUMANIZED MOUSE AND RAT MODEL MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 62 EUROPE: HUMANIZED MOUSE AND RAT MODEL MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 63 ASIA PACIFIC: HUMANIZED MOUSE AND RAT MODEL MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2021–2028 (USD MILLION)
8 HUMANIZED MOUSE AND RAT MODEL MARKET, BY END USER
8.1 INTRODUCTION
TABLE 64 HUMANIZED MOUSE AND RAT MODEL MARKET, BY END USER, 2021–2028 (USD MILLION)
8.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
8.2.1 INCREASING EXPENDITURE ON R&D FOR DRUG DEVELOPMENT TO DRIVE MARKET
TABLE 65 HUMANIZED MOUSE AND RAT MODEL MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2021–2028 (USD MILLION)
TABLE 66 NORTH AMERICA: HUMANIZED MOUSE AND RAT MODEL MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 67 EUROPE: HUMANIZED MOUSE AND RAT MODEL MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 68 ASIA PACIFIC: HUMANIZED MOUSE AND RAT MODEL MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2021–2028 (USD MILLION)
8.3 CONTRACT RESEARCH ORGANIZATIONS AND CONTRACT DEVELOPMENT MANUFACTURING ORGANIZATIONS
8.3.1 RISING OUTSOURCING OF DRUG DISCOVERY SERVICES BY PHARMA & BIOTECH COMPANIES TO PROPEL MARKET
TABLE 69 HUMANIZED MOUSE AND RAT MODEL MARKET FOR CROS AND CDMOS, BY REGION, 2021–2028 (USD MILLION)
TABLE 70 NORTH AMERICA: HUMANIZED MOUSE AND RAT MODEL MARKET FOR CROS AND CDMOS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 71 EUROPE: HUMANIZED MOUSE AND RAT MODEL MARKET FOR CROS AND CDMOS, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 72 ASIA PACIFIC: HUMANIZED MOUSE AND RAT MODEL MARKET FOR CROS AND CDMOS, BY COUNTRY, 2021–2028 (USD MILLION)
8.4 ACADEMIC & RESEARCH INSTITUTES
8.4.1 SUPPORTIVE FUNDING INVESTMENTS FOR LIFE SCIENCE RESEARCH TO SUPPORT MARKET GROWTH
TABLE 73 HUMANIZED MOUSE AND RAT MODEL MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2021–2028 (USD MILLION)
TABLE 74 NORTH AMERICA: HUMANIZED MOUSE AND RAT MODEL MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 75 EUROPE: HUMANIZED MOUSE AND RAT MODEL MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 76 ASIA PACIFIC: HUMANIZED MOUSE AND RAT MODEL MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2021–2028 (USD MILLION)
9 HUMANIZED MOUSE AND RAT MODEL MARKET, BY REGION
9.1 INTRODUCTION
TABLE 77 HUMANIZED MOUSE AND RAT MODEL MARKET, BY REGION, 2021–2028 (USD MILLION)
9.2 NORTH AMERICA
FIGURE 20 HUMANIZED MOUSE AND RAT MODEL MARKET: NORTH AMERICA SNAPSHOT
TABLE 78 NORTH AMERICA: HUMANIZED MOUSE AND RAT MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 79 NORTH AMERICA: HUMANIZED MOUSE AND RAT MODEL MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 80 NORTH AMERICA: HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 81 NORTH AMERICA: CELL-BASED HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 82 NORTH AMERICA: HUMANIZED MOUSE AND RAT MODEL MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 83 NORTH AMERICA: HUMANIZED MOUSE AND RAT MODEL MARKET, BY END USER, 2021–2028 (USD MILLION)
9.2.1 US
9.2.1.1 Growing research initiatives on mAbs and biosimilars to drive market
TABLE 84 US: HUMANIZED MOUSE AND RAT MODEL MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 85 US: HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 86 US: CELL-BASED HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 87 US: HUMANIZED MOUSE AND RAT MODEL MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 88 US: HUMANIZED MOUSE AND RAT MODEL MARKET, BY END USER, 2021–2028 (USD MILLION)
9.2.2 CANADA
9.2.2.1 Government initiatives on stem cell research to drive market
TABLE 89 CANADA: HUMANIZED MOUSE AND RAT MODEL MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 90 CANADA: HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 91 CANADA: CELL-BASED HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 92 CANADA: HUMANIZED MOUSE AND RAT MODEL MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 93 CANADA: HUMANIZED MOUSE AND RAT MODEL MARKET, BY END USER, 2021–2028 (USD MILLION)
9.2.3 NORTH AMERICA: RECESSION IMPACT
9.3 EUROPE
TABLE 94 EUROPE: HUMANIZED MOUSE AND RAT MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 95 EUROPE: HUMANIZED MOUSE AND RAT MODEL MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 96 EUROPE: HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 97 EUROPE: CELL-BASED HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 98 EUROPE: HUMANIZED MOUSE AND RAT MODEL MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 99 EUROPE: HUMANIZED MOUSE AND RAT MODEL MARKET, BY END USER, 2021–2028 (USD MILLION)
9.3.1 GERMANY
9.3.1.1 Rising pharmaceutical R&D expenditure to drive market
TABLE 100 GERMANY: HUMANIZED MOUSE AND RAT MODEL MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 101 GERMANY: HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 102 GERMANY: CELL-BASED HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 103 GERMANY: HUMANIZED MOUSE AND RAT MODEL MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 104 GERMANY: HUMANIZED MOUSE AND RAT MODEL MARKET, BY END USER, 2021–2028 (USD MILLION)
9.3.2 UK
9.3.2.1 Growing investments in cancer research to drive market
TABLE 105 UK: HUMANIZED MOUSE AND RAT MODEL MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 106 UK: HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 107 UK: CELL-BASED HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 108 UK: HUMANIZED MOUSE AND RAT MODEL MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 109 UK: HUMANIZED MOUSE AND RAT MODEL MARKET, BY END USER, 2021–2028 (USD MILLION)
9.3.3 FRANCE
9.3.3.1 Increasing initiatives for genomics research to support market growth
TABLE 110 FRANCE: HUMANIZED MOUSE AND RAT MODEL MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 111 FRANCE: HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 112 FRANCE: CELL-BASED HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 113 FRANCE: HUMANIZED MOUSE AND RAT MODEL MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 114 FRANCE: HUMANIZED MOUSE AND RAT MODEL MARKET, BY END USER, 2021–2028 (USD MILLION)
9.3.4 ITALY
9.3.4.1 Rising R&D spending on pharmaceutical production to fuel market
TABLE 115 ITALY: HUMANIZED MOUSE AND RAT MODEL MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 116 ITALY: HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 117 ITALY: CELL-BASED HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 118 ITALY: HUMANIZED MOUSE AND RAT MODEL MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 119 ITALY: HUMANIZED MOUSE AND RAT MODEL MARKET, BY END USER, 2021–2028 (USD MILLION)
9.3.5 SPAIN
9.3.5.1 Rising growth in biotech industry to drive market
TABLE 120 SPAIN: HUMANIZED MOUSE AND RAT MODEL MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 121 SPAIN: HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 122 SPAIN: CELL-BASED HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 123 SPAIN: HUMANIZED MOUSE AND RAT MODEL MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 124 SPAIN: HUMANIZED MOUSE AND RAT MODEL MARKET, BY END USER, 2021–2028 (USD MILLION)
9.3.6 REST OF EUROPE
TABLE 125 REST OF EUROPE: HUMANIZED MOUSE AND RAT MODEL MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 126 REST OF EUROPE: HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 127 REST OF EUROPE: CELL-BASED HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 128 REST OF EUROPE: HUMANIZED MOUSE AND RAT MODEL MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 129 REST OF EUROPE: HUMANIZED MOUSE AND RAT MODEL MARKET, BY END USER, 2021–2028 (USD MILLION)
9.3.7 EUROPE: RECESSION IMPACT
9.4 ASIA PACIFIC
FIGURE 21 HUMANIZED MOUSE AND RAT MODEL MARKET: ASIA PACIFIC SNAPSHOT
TABLE 130 ASIA PACIFIC: HUMANIZED MOUSE AND RAT MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 131 ASIA PACIFIC: HUMANIZED MOUSE AND RAT MODEL MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 132 ASIA PACIFIC: HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 133 ASIA PACIFIC: CELL-BASED HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 134 ASIA PACIFIC: HUMANIZED MOUSE AND RAT MODEL MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 135 ASIA PACIFIC: HUMANIZED MOUSE AND RAT MODEL MARKET, BY END USER, 2021–2028 (USD MILLION)
9.4.1 CHINA
9.4.1.1 High growth in pharmaceutical industry to drive market
TABLE 136 CHINA: HUMANIZED MOUSE AND RAT MODEL MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 137 CHINA: HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 138 CHINA: CELL-BASED HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 139 CHINA: HUMANIZED MOUSE AND RAT MODEL MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 140 CHINA: HUMANIZED MOUSE AND RAT MODEL MARKET, BY END USER, 2021–2028 (USD MILLION)
9.4.2 JAPAN
9.4.2.1 Growing research collaborations among pharmaceutical companies to drive market
TABLE 141 JAPAN: HUMANIZED MOUSE AND RAT MODEL MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 142 JAPAN: HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 143 JAPAN: CELL-BASED HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 144 JAPAN: HUMANIZED MOUSE AND RAT MODEL MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 145 JAPAN: HUMANIZED MOUSE AND RAT MODEL MARKET, BY END USER, 2021–2028 (USD MILLION)
9.4.3 INDIA
9.4.3.1 Growth in biotech industry to drive market
TABLE 146 INDIA: HUMANIZED MOUSE AND RAT MODEL MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 147 INDIA: HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 148 INDIA: CELL-BASED HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 149 INDIA: HUMANIZED MOUSE AND RAT MODEL MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 150 INDIA: HUMANIZED MOUSE AND RAT MODEL MARKET, BY END USER, 2021–2028 (USD MILLION)
9.4.4 SOUTH KOREA
9.4.4.1 Rising government-funded investments for pharmaceutical R&D to drive market
TABLE 151 SOUTH KOREA: HUMANIZED MOUSE AND RAT MODEL MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 152 SOUTH KOREA: HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 153 SOUTH KOREA: CELL-BASED HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 154 SOUTH KOREA: HUMANIZED MOUSE AND RAT MODEL MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 155 SOUTH KOREA: HUMANIZED MOUSE AND RAT MODEL MARKET, BY END USER, 2021–2028 (USD MILLION)
9.4.5 REST OF ASIA PACIFIC
TABLE 156 REST OF ASIA PACIFIC: HUMANIZED MOUSE AND RAT MODEL MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 157 REST OF ASIA PACIFIC: HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 158 REST OF ASIA PACIFIC: CELL-BASED HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 159 REST OF ASIA PACIFIC: HUMANIZED MOUSE AND RAT MODEL MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 160 REST OF ASIA PACIFIC: HUMANIZED MOUSE AND RAT MODEL MARKET, BY END USER, 2021–2028 (USD MILLION)
9.4.6 ASIA PACIFIC: RECESSION IMPACT
9.5 LATIN AMERICA
9.5.1 GROWING PRESENCE OF PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES TO PROPEL MARKET
TABLE 161 LATIN AMERICA: HUMANIZED MOUSE AND RAT MODEL MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 162 LATIN AMERICA: HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 163 LATIN AMERICA: CELL-BASED HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 164 LATIN AMERICA: HUMANIZED MOUSE AND RAT MODEL MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 165 LATIN AMERICA: HUMANIZED MOUSE AND RAT MODEL MARKET, BY END USER, 2021–2028 (USD MILLION)
9.5.2 LATIN AMERICA: RECESSION IMPACT
9.6 MIDDLE EAST & AFRICA
9.6.1 RISING INITIATIVES FOR CLINICAL TESTING TO SUPPORT MARKET GROWTH
TABLE 166 MIDDLE EAST & AFRICA: HUMANIZED MOUSE AND RAT MODEL MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 167 MIDDLE EAST & AFRICA: HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 168 MIDDLE EAST & AFRICA: CELL-BASED HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2021–2028 (USD MILLION)
TABLE 169 MIDDLE EAST & AFRICA: HUMANIZED MOUSE AND RAT MODEL MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 170 MIDDLE EAST & AFRICA: HUMANIZED MOUSE AND RAT MODEL MARKET, BY END USER, 2021–2028 (USD MILLION)
9.6.2 MIDDLE EAST & AFRICA: RECESSION IMPACT
10 COMPETITIVE LANDSCAPE
10.1 OVERVIEW
10.2 STRATEGIES ADOPTED BY KEY PLAYERS
FIGURE 22 HUMANIZED MOUSE AND RAT MODEL MARKET: KEY STRATEGIES ADOPTED BY MARKET PLAYERS (2019?2023)
10.3 MARKET SHARE ANALYSIS
FIGURE 23 HUMANIZED MOUSE AND RAT MODEL MARKET SHARE FOR KEY PLAYERS (2022)
TABLE 171 HUMANIZED MOUSE AND RAT MODEL MARKET: INTENSITY OF COMPETITIVE RIVALRY
10.4 COMPANY EVALUATION MATRIX
10.4.1 STARS
10.4.2 EMERGING LEADERS
10.4.3 PERVASIVE PLAYERS
10.4.4 PARTICIPANTS
FIGURE 24 HUMANIZED MOUSE AND RAT MODEL MARKET: COMPANY EVALUATION MATRIX OF LEADING PLAYERS (2022)
10.5 COMPANY EVALUATION MATRIX FOR STARTUPS/SMES
10.5.1 PROGRESSIVE COMPANIES
10.5.2 STARTING BLOCKS
10.5.3 RESPONSIVE COMPANIES
10.5.4 DYNAMIC COMPANIES
10.6 HUMANIZED MOUSE AND RAT MODEL MARKET: FOOTPRINT ANALYSIS OF COMPANIES
TABLE 172 HUMANIZED MOUSE AND RAT MODEL MARKET: PRODUCT FOOTPRINT ANALYSIS (2022)
TABLE 173 HUMANIZED MOUSE AND RAT MODEL MARKET: END-USER FOOTPRINT ANALYSIS
TABLE 174 HUMANIZED MOUSE AND RAT MODEL MARKET: REGIONAL FOOTPRINT ANALYSIS (2022)
10.7 COMPETITIVE SCENARIO AND TRENDS
TABLE 175 HUMANIZED MOUSE AND RAT MODEL MARKET: PRODUCT LAUNCHES
TABLE 176 HUMANIZED MOUSE AND RAT MODEL MARKET: DEALS
11 COMPANY PROFILES
11.1 KEY PLAYERS
(Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats))*
11.1.1 CHARLES RIVER LABORATORIES
TABLE 177 CHARLES RIVER LABORATORIES: BUSINESS OVERVIEW
FIGURE 26 CHARLES RIVER LABORATORIES: COMPANY SNAPSHOT (2022)
11.1.2 THE JACKSON LABORATORY
TABLE 178 THE JACKSON LABORATORY: BUSINESS OVERVIEW
FIGURE 27 THE JACKSON LABORATORY: COMPANY SNAPSHOT (2022)
11.1.3 INOTIV
TABLE 179 INOTIV: COMPANY OVERVIEW
FIGURE 28 INOTIV: COMPANY SNAPSHOT
11.1.4 TACONIC BIOSCIENCES, INC.
TABLE 180 TACONIC BIOSCIENCES, INC.: BUSINESS OVERVIEW
11.1.5 CROWN BIOSCIENCE
TABLE 181 CROWN BIOSCIENCE: BUSINESS OVERVIEW
11.1.6 CHAMPIONS ONCOLOGY, INC.
TABLE 182 CHAMPIONS ONCOLOGY, INC.: BUSINESS OVERVIEW
FIGURE 29 CHAMPIONS ONCOLOGY, INC.: COMPANY SNAPSHOT (2022)
11.1.7 HERA BIOLABS
TABLE 183 HERA BIOLABS: BUSINESS OVERVIEW
11.1.8 GENOWAY
TABLE 184 GENOWAY: BUSINESS OVERVIEW
11.1.9 VITALSTAR BIOTECHNOLOGY
TABLE 185 VITALSTAR BIOTECHNOLOGY: BUSINESS OVERVIEW
11.1.10 INGENIOUS TARGETING LABORATORY
TABLE 186 INGENIOUS TARGETING LABORATORY: BUSINESS OVERVIEW
11.1.11 TRANS GENIC
TABLE 187 TRANS GENIC: BUSINESS OVERVIEW
FIGURE 30 TRANS GENIC: COMPANY SNAPSHOT
11.1.12 HARBOUR ANTIBODIES BV (A SUBSIDIARY OF HARBOUR BIOMED)
TABLE 188 HARBOUR ANTIBODIES BV: BUSINESS OVERVIEW
FIGURE 31 HARBOUR BIOMED: COMPANY SNAPSHOT
11.1.13 ONCODESIGN
TABLE 189 ONCODESIGN: BUSINESS OVERVIEW
11.1.14 PHARMATEST SERVICES
TABLE 190 PHARMATEST SERVICES: BUSINESS OVERVIEW
11.2 OTHER PLAYERS
11.2.1 OZGENE PTY LTD.
11.2.2 TRANSCURE BIOSERVICES
11.2.3 CYAGEN BIOSCIENCES
11.2.4 ARAGEN LIFE SCIENCES LTD. (FORMERLY GVK BIO)
11.2.5 BIOCYTOGEN
11.2.6 GEMPHARMATECH
*Details on Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats) might not be captured in case of unlisted companies.
12 APPENDIX
12.1 DISCUSSION GUIDE
12.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
12.3 CUSTOMIZATION OPTIONS
12.4 RELATED REPORTS
12.5 AUTHOR DETAILS
